<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588677</url>
  </required_header>
  <id_info>
    <org_study_id>AB10015</org_study_id>
    <nct_id>NCT02588677</nct_id>
  </id_info>
  <brief_title>Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to compare the efficacy and safety of masitinib in combination with riluzole
      in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Masitinib is novel tyrosine kinase inhibitor that targets microglia and mast cells through
      inhibiting a limited number of kinases. Masitinib blocks microglia proliferation and
      activation, and mast cell-mediated degranulation, the release of cytotoxic substances that
      might further damage the motor nerves.

      There are two distinct populations of ALS patients: population of &quot;Normal progressors&quot; and
      population of &quot;Faster progressors&quot;. Targeted population for primary analysis is population of
      &quot;Normal progressors&quot;.

      &quot;Normal progressors&quot; are ALS patients whose progression of ALSFRS-R score before
      randomization is less than 1.1 point per month.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">December 5, 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised</measure>
    <time_frame>From baseline to week 48</time_frame>
    <description>The amyotrophic lateral sclerosis functional rating scale (ALSFRS), which is a Validated instrument that assesses the functional status and the disease progression in patients with amyotrophic lateral sclerosis (ALS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Forced Vital Capacity (FVC)</measure>
    <time_frame>From baseline to week 48</time_frame>
    <description>Forced vital capacity (FVC) measures the volume of air expelled from the lungs during a quick, forceful breath.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Time from the randomization date until the earliest date for a decline of more than 9-points in ALSFRS-R score, asssesd over a maximum of 60 months</time_frame>
    <description>Progression Free Survival is defined as the time from the randomization date until the earliest date for a decline of more than 9-points in ALSFRS-R score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from the randomization date until death, asssesd over a maximum of 60 months</time_frame>
    <description>Overall survival is defined as time in months from the randomization date to the date of death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">394</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>Masitinib (3.0) &amp; Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib 3 mg/kg/day + riluzole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Masitinib (4.5) &amp; Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib 4.5 mg/kg/day (2) + riluzole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Riluzole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib (4.5)</intervention_name>
    <description>4.5 mg/kg/day</description>
    <arm_group_label>Masitinib (4.5) &amp; Riluzole</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <arm_group_label>Masitinib (3.0) &amp; Riluzole</arm_group_label>
    <arm_group_label>Masitinib (4.5) &amp; Riluzole</arm_group_label>
    <arm_group_label>Placebo &amp; Riluzole</arm_group_label>
    <other_name>Rilutek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo &amp; Riluzole</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib (3.0)</intervention_name>
    <description>3 mg/kg/day</description>
    <arm_group_label>Masitinib (3.0) &amp; Riluzole</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Main inclusion criteria:

          1. Familial or sporadic ALS

          2. Patient diagnosed with probable of definite ALS

          3. Patient treated with a stable dose of riluzole (100 mg/day) for at least 30 days prior
             to screening

        Exclusion Criteria:

        1. Patient who underwent tracheostomy and/or gastrostomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesus S Mora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad de ELA, Hospital San Rafael, c/ Serrano, 199, 28016 Madrid, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Carlos III</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <disposition_first_submitted>December 12, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>December 12, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 14, 2018</disposition_first_posted>
  <last_update_submitted>December 13, 2018</last_update_submitted>
  <last_update_submitted_qc>December 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis (ALS) - masitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

